AtriCure price target raised to $79 from $74 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on AtriCure to $79 from $74 and keeps a Buy rating on the shares. The analyst said with multiple potential long-term growth catalysts from the company’s ongoing clinical trial work, we still believe that AtriCure has a solid long-term setup,